Novartis AG (NVS)
USD 96.83
(-2.29%)
USD 96.83
(-2.29%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 24.87 Billion USD | -10.04% |
| 2022 | 27.14 Billion USD | 7.2% |
| 2021 | 25.32 Billion USD | 2.83% |
| 2020 | 24.62 Billion USD | -2.15% |
| 2019 | 25.16 Billion USD | -5.36% |
| 2018 | 26.59 Billion USD | 9.28% |
| 2017 | 24.33 Billion USD | 2.89% |
| 2016 | 23.64 Billion USD | -1.49% |
| 2015 | 24 Billion USD | -4.74% |
| 2014 | 25.2 Billion USD | -10.99% |
| 2013 | 28.31 Billion USD | 3.73% |
| 2012 | 27.29 Billion USD | -7.14% |
| 2011 | 29.39 Billion USD | 15.06% |
| 2010 | 25.54 Billion USD | 11.35% |
| 2009 | 22.94 Billion USD | 3.43% |
| 2008 | 22.18 Billion USD | 4.95% |
| 2007 | 21.13 Billion USD | 14.23% |
| 2006 | 18.5 Billion USD | 10.43% |
| 2005 | 16.75 Billion USD | 11.07% |
| 2004 | 15.08 Billion USD | 15.3% |
| 2003 | 13.08 Billion USD | 8.32% |
| 2002 | 12.07 Billion USD | 18.58% |
| 2001 | 10.18 Billion USD | -5.54% |
| 2000 | 10.78 Billion USD | 1.99% |
| 1999 | 10.57 Billion USD | 1.76% |
| 1998 | 10.38 Billion USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 6.31 Billion USD | 17.59% |
| 2024 Q1 | 5.07 Billion USD | -17.85% |
| 2024 Q2 | 5.36 Billion USD | 5.86% |
| 2023 Q4 | 6.17 Billion USD | -14.43% |
| 2023 FY | 24.41 Billion USD | -10.04% |
| 2023 Q1 | 6.42 Billion USD | -9.12% |
| 2023 Q2 | 6.67 Billion USD | 3.96% |
| 2023 Q3 | 7.21 Billion USD | 8.06% |
| 2022 Q2 | 7.1 Billion USD | 16.38% |
| 2022 Q3 | 6.86 Billion USD | -3.35% |
| 2022 Q4 | 7.06 Billion USD | 2.87% |
| 2022 FY | 27.14 Billion USD | 7.2% |
| 2022 Q1 | 6.1 Billion USD | -12.57% |
| 2021 Q2 | 5.9 Billion USD | -5.43% |
| 2021 Q4 | 6.98 Billion USD | 12.72% |
| 2021 FY | 25.32 Billion USD | 2.83% |
| 2021 Q1 | 6.24 Billion USD | 1.15% |
| 2021 Q3 | 6.19 Billion USD | 5.0% |
| 2020 Q3 | 6.37 Billion USD | 9.11% |
| 2020 FY | 24.62 Billion USD | -2.15% |
| 2020 Q1 | 6.24 Billion USD | -9.55% |
| 2020 Q4 | 6.16 Billion USD | -3.2% |
| 2020 Q2 | 5.84 Billion USD | -6.42% |
| 2019 Q4 | 6.9 Billion USD | 8.71% |
| 2019 Q1 | 5.96 Billion USD | -19.85% |
| 2019 Q3 | 6.34 Billion USD | 6.6% |
| 2019 FY | 25.16 Billion USD | -5.36% |
| 2019 Q2 | 5.95 Billion USD | -0.12% |
| 2018 Q1 | 6.12 Billion USD | -7.24% |
| 2018 Q4 | 7.43 Billion USD | 30.88% |
| 2018 FY | 26.59 Billion USD | 9.28% |
| 2018 Q3 | 5.68 Billion USD | -12.43% |
| 2018 Q2 | 6.49 Billion USD | 5.94% |
| 2017 Q3 | 6.01 Billion USD | 0.94% |
| 2017 FY | 24.33 Billion USD | 2.89% |
| 2017 Q4 | 6.6 Billion USD | 9.86% |
| 2017 Q2 | 5.95 Billion USD | 3.44% |
| 2017 Q1 | 5.75 Billion USD | -13.57% |
| 2016 FY | 23.64 Billion USD | -1.49% |
| 2016 Q4 | 6.66 Billion USD | 16.8% |
| 2016 Q3 | 5.7 Billion USD | -7.03% |
| 2016 Q2 | 6.13 Billion USD | 19.2% |
| 2016 Q1 | 5.14 Billion USD | -21.75% |
| 2015 Q2 | 6.12 Billion USD | 12.71% |
| 2015 Q1 | 5.43 Billion USD | -17.46% |
| 2015 FY | 24 Billion USD | -4.74% |
| 2015 Q3 | 5.86 Billion USD | -4.32% |
| 2015 Q4 | 6.57 Billion USD | 12.2% |
| 2014 Q4 | 6.58 Billion USD | 7.28% |
| 2014 FY | 25.2 Billion USD | -10.99% |
| 2014 Q3 | 6.14 Billion USD | -3.87% |
| 2014 Q2 | 6.38 Billion USD | 5.97% |
| 2014 Q1 | 6.02 Billion USD | -21.5% |
| 2013 Q4 | 7.67 Billion USD | 10.05% |
| 2013 Q3 | 6.97 Billion USD | 0.33% |
| 2013 FY | 28.31 Billion USD | 3.73% |
| 2013 Q2 | 6.95 Billion USD | 3.73% |
| 2013 Q1 | 6.7 Billion USD | -10.61% |
| 2012 Q3 | 6.43 Billion USD | -4.54% |
| 2012 Q4 | 7.5 Billion USD | 16.51% |
| 2012 FY | 27.29 Billion USD | -7.14% |
| 2012 Q1 | 6.61 Billion USD | -22.74% |
| 2012 Q2 | 6.74 Billion USD | 1.95% |
| 2011 Q4 | 8.56 Billion USD | 17.35% |
| 2011 FY | 29.39 Billion USD | 15.06% |
| 2011 Q2 | 7.18 Billion USD | 13.0% |
| 2011 Q3 | 7.29 Billion USD | 1.57% |
| 2011 Q1 | 6.35 Billion USD | -14.95% |
| 2010 Q3 | 6.57 Billion USD | 14.2% |
| 2010 FY | 25.54 Billion USD | 11.35% |
| 2010 Q1 | 5.74 Billion USD | -15.96% |
| 2010 Q2 | 5.75 Billion USD | 0.09% |
| 2010 Q4 | 7.47 Billion USD | 13.73% |
| 2009 Q3 | 5.55 Billion USD | -0.02% |
| 2009 Q1 | 4.99 Billion USD | -14.4% |
| 2009 Q2 | 5.55 Billion USD | 11.21% |
| 2009 Q4 | 6.84 Billion USD | 23.19% |
| 2009 FY | 22.94 Billion USD | 3.43% |
| 2008 Q3 | 5.67 Billion USD | 1.45% |
| 2008 Q4 | 5.83 Billion USD | 2.82% |
| 2008 FY | 22.18 Billion USD | 4.95% |
| 2008 Q2 | 5.59 Billion USD | 10.1% |
| 2008 Q1 | 5.08 Billion USD | -25.85% |
| 2007 Q4 | 6.85 Billion USD | 44.47% |
| 2007 Q2 | 4.85 Billion USD | 4.11% |
| 2007 Q1 | 4.66 Billion USD | -10.37% |
| 2007 FY | 21.13 Billion USD | 14.23% |
| 2007 Q3 | 4.74 Billion USD | -2.39% |
| 2006 Q3 | 4.71 Billion USD | 0.28% |
| 2006 FY | 18.5 Billion USD | 10.43% |
| 2006 Q2 | 4.7 Billion USD | 21.16% |
| 2006 Q4 | 5.2 Billion USD | 10.44% |
| 2006 Q1 | 3.88 Billion USD | -18.28% |
| 2005 FY | 16.75 Billion USD | 11.07% |
| 2005 Q1 | 3.8 Billion USD | -8.51% |
| 2005 Q2 | 4.04 Billion USD | 6.25% |
| 2005 Q3 | 4.15 Billion USD | 2.6% |
| 2005 Q4 | 4.74 Billion USD | 14.38% |
| 2004 Q2 | 3.58 Billion USD | -0.67% |
| 2004 Q1 | 3.6 Billion USD | 2.65% |
| 2004 Q3 | 3.72 Billion USD | 3.96% |
| 2004 Q4 | 4.16 Billion USD | 11.67% |
| 2004 FY | 15.08 Billion USD | 15.3% |
| 2003 Q1 | 3 Billion USD | -27.66% |
| 2003 Q3 | 3.24 Billion USD | -2.29% |
| 2003 FY | 13.08 Billion USD | 8.32% |
| 2003 Q4 | 3.51 Billion USD | 8.49% |
| 2003 Q2 | 3.31 Billion USD | 10.31% |
| 2002 Q2 | 2.85 Billion USD | 0.0% |
| 2002 Q1 | - USD | 100.0% |
| 2002 FY | 12.07 Billion USD | 18.58% |
| 2002 Q4 | 4.15 Billion USD | 59.52% |
| 2002 Q3 | 2.6 Billion USD | -8.85% |
| 2001 Q1 | - USD | 100.0% |
| 2001 FY | 10.18 Billion USD | -5.54% |
| 2001 Q3 | - USD | -100.0% |
| 2001 Q4 | -14.94 Billion USD | 0.0% |
| 2001 Q2 | 2.28 Billion USD | 0.0% |
| 2000 FY | 10.78 Billion USD | 1.99% |
| 2000 Q4 | -17.02 Billion USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | 2.95 Billion USD | 0.0% |
| 2000 Q3 | - USD | -100.0% |
| 1999 FY | 10.57 Billion USD | 1.76% |
| 1998 FY | 10.38 Billion USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbbVie Inc. | 24.83 Billion USD | -0.145% |
| Bristol-Myers Squibb Company | 34.31 Billion USD | 27.517% |
| Bristol-Myers Squibb Company Ce | 34.31 Billion USD | 27.517% |
| Johnson & Johnson | 58.6 Billion USD | 57.562% |
| Eli Lilly and Company | 16.71 Billion USD | -48.781% |
| Merck & Co., Inc. | 43.98 Billion USD | 43.461% |
| Organon & Co. | 2.41 Billion USD | -928.152% |
| Pfizer Inc. | 25.45 Billion USD | 2.275% |